What changed: Ductal carcinoma in situ (DCIS)
Every dated change on the records linked to Ductal carcinoma in situ (DCIS), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 2
- 2024GuidelineDuctal carcinoma in situ (DCIS)Guideline COMET (JAMA 2024): Low-risk DCIS
Active monitoring with mammography every six months and optional endocrine therapy, in trials (COMET, LORIS, LORD) or after shared decision-making where guidelines allow.
- 2024MilestoneActive surveillanceCOMET: active monitoring non-inferior at two years
Hwang and colleagues (JAMA, December 2024); first randomised evidence for monitoring low-risk DCIS.
2019 · 1
2016 · 2
- 2016GuidelineDuctal carcinoma in situ (DCIS)Guideline NCCN Guidelines: Breast Cancer; SSO-ASTRO-ASCO margin guideline 2016: Localised DCIS, breast conservation
Lumpectomy to 2 mm margins followed by whole-breast radiotherapy (hypofractionated), with radiotherapy omission considered for low-risk lesions (RTOG 9804 criteria or genomic assay). (NCCN Category 1 (radiotherapy after lumpectomy))
- 2016MilestoneLumpectomy (breast-conserving surgery)2 mm margin standard (SSO-ASTRO-ASCO)
A milestone in how this cancer is treated.